Fig. 3

Synergistic mobilization by HF51116 and G-CSF. a One hundred micrograms per kilogram G-CSF was subcutaneously injected (s.c.) into C57BL/6 mice every 12 h for 4 days. Saline, 5 mg/kg HF51116, or 5 mg/kg AMD3100 was subcutaneously injected (s.c.) at 12 h post-final G-CSF injection. Total CFU numbers were tested at 0, 30, and 60 min post-injection (mean ± SEM of n = 16 mice). ****P < 0.0001, ***P < 0.001, **P < 0.01; ns, not significant. b–e The absolute number of LSK and SLAM-LSK cells in peripheral blood post different treatments. The treatment regimen was the same as described in a. Counting of b, c HSPCs (LSK: Lineage⁻ Sca-1⁺ c-Kit⁺) and d, e HSCs (SLAM LSK: lineage⁻ Sca-1⁺ c-Kit⁺ CD150⁺ CD48⁻) were analyzed through flow cytometry (mean ± SEM of n = 3 mice for the G-CSF and G-CSF+AMD3100 group, n = 4 mice for the G-CSF+HF51116 group)